3 research outputs found
Structure of Erm-modified 70S ribosome reveals the mechanism of macrolide resistance
Many antibiotics inhibit bacterial growth by binding to the ribosome and interfering with protein biosynthesis. Macrolides represent one of the most successful classes of ribosome-targeting antibiotics. The main clinically relevant mechanism of resistance to macrolides is dimethylation of the 23S rRNA nucleotide A2058, located in the drug-binding site, a reaction catalyzed by Erm-type rRNA methyltransferases. Here, we present the crystal structure of the Erm-dimethylated 70S ribosome at 2.4 Å resolution, together with the structures of unmethylated 70S ribosome functional complexes alone or in combination with macrolides. Altogether, our structural data do not support previous models and, instead, suggest a principally new explanation of how A2058 dimethylation confers resistance to macrolides. Moreover, high-resolution structures of two macrolide antibiotics bound to the unmodified ribosome reveal a previously unknown role of the desosamine moiety in drug binding, laying a foundation for the rational knowledge-based design of macrolides that can overcome Erm-mediated resistance
Peptide inhibitors of bacterial protein synthesis with broad spectrum and SbmA-independent bactericidal activity against clinical pathogens.
Proline-rich antimicrobial peptides (PrAMPs) are promising lead compounds for developing new antimicrobials, however their narrow spectrum of action is limiting. PrAMPs kill bacteria binding to their ribosomes and inhibiting protein synthesis. In this study, 133 derivatives of the PrAMP Bac7(1-16) were synthesized to identify the crucial residues for ribosome inactivation and antimicrobial activity. Then, five new Bac7(1-16) derivatives were conceived and characterized by antibacterial and membrane permeabilization assays, by X-ray crystallography and molecular dynamics simulations. Some derivatives displayed broad spectrum activity, encompassing Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Staphylococcus aureus. Two peptides out of five, acquired a weak membrane-perturbing activity, while maintaining the ability to inhibit protein synthesis. These derivatives became independent of the SbmA transporter, commonly used by native PrAMPs, suggesting that they obtained a novel route to enter bacterial cells. PrAMP-derived compounds could become new-generation antimicrobials to combat the antibiotic-resistant pathogens
A Synthetic Antibiotic Scaffold Effective Against Multidrug-Resistant Bacterial Pathogens
The
dearth of new medicines effective against antibiotic-resistant bacteria
presents a growing global public health concern. For more than five decades,
the search for new antibiotics has relied heavily upon the chemical
modification of natural products (semi-synthesis), a method ill-equipped to
combat rapidly evolving resistance threats. Semi-synthetic modifications are
typically of limited scope within polyfunctional antibiotics, usually increase
molecular weight, and seldom permit modifications of the underlying scaffold.
When properly designed, fully synthetic routes can easily address these
shortcomings. Here we report the structure-guided design and component-based
synthesis of a rigid oxepanoproline scaffold which, when linked to the
aminooctose residue of clindamycin, produces an antibiotic of exceptional
potency and spectrum of activity, here named iboxamycin. Iboxamycin is
effective in strains expressing Erm and Cfr rRNA methyltransferase enzymes,
products of genes that confer resistance to all clinically relevant antibiotics
targeting the large ribosomal subunit, namely macrolides, lincosamides,
phenicols, oxazolidinones, pleuromutilins, and streptogramins. X-ray
crystallographic studies of iboxamycin in complex with the native 70S bacterial
ribosome, as well as the Erm-methylated 70S ribosome, uncover the structural
basis for this enhanced activity, including an unforeseen and unprecedented
displacement of
upon antibiotic binding. In mice, iboxamycin
is orally bioavailable, safe, and effective in treating bacterial infections, testifying
to the capacity for chemical synthesis to provide new antibiotics in an era of
rising resistance